Carper, Coons, Blunt Rochester Announce $10 Million for University of Delaware’s NIIMBL
Washington, September 29, 2023
WASHINGTON - Today, U.S. Senators Tom Carper and Chris Coons, along with Congresswoman Lisa Blunt Rochester (all D-Del.), announced a $10 million grant to the University of Delaware’s National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). This funding was secured by Carper, Coons, and Blunt Rochester through the federal congressionally directed spending process.
The funding will support the construction of a Good Manufacturing Practices (cGMP) facility, slated to be called the SABRE Center (Securing American Bio-Manufacturing Research and Education). The facility will be located north of NIIMBL’s current location on the University of Delaware’s STAR Campus and will support NIIMBL’s work in biopharmaceutical innovation, allowing for space for the clinical research and production of biopharmaceutical products to address future public health threats.
“The STAR Campus continues to shine as a hub for innovation and research, and remains an economic driver for our state,” said Senator Carper. “What was once a shuttered auto-assembly plant has become a first-class research campus, and I am so proud we could deliver this critical funding to support NIIMBL’s life-saving research.”
“Investing in NIIMBL means investing in the health of our families, the competitiveness of our economy, and the growth of Delaware as a hub for biotechnology and biomanufacturing,” said Senator Coons. “I am thrilled to have secured $10 million in additional Congressionally Directed Spending to support biopharmaceutical innovation and help ensure our state remains a global leader in research and innovation, while creating good-paying jobs and helping address future public health challenges.”
“NIIMBL is a critical partner in supporting the health, wealth, and competitiveness of our state and nation,” said Rep. Blunt Rochester. “Today’s announcement of $10 million in federal funding for NIIMBL will support its large-scale innovation – from advanced research and development to the manufacturing of biopharmaceuticals to help address future public health threats – in a new, state-of-the-art facility. I’m proud to have secured this funding alongside Senator Carper and Senator Coons to foster our innovative spirit and create good-paying jobs, and I look forward to watching NIIMBL’s footprint expand here in Delaware and beyond.”
"This funding will help build new capabilities that will accelerate and enhance our country's ability to stay at the leading edge of biopharmaceutical manufacturing innovation and ensure we have a world-leading biomanufacturing workforce," said Kelvin Lee, Institute Director for NIIMBL.